amitriptylin orifarm 25 mg
orifarm generics a/s - amitriptylinhydroklorid - tablett, filmdrasjert - 25 mg
amitriptylin orifarm 10 mg
orifarm generics a/s - amitriptylinhydroklorid - tablett, filmdrasjert - 10 mg
amitriptylin abcur 50 mg
abcur ab - amitriptylinhydroklorid - tablett, filmdrasjert - 50 mg
amitriptylin abcur 10 mg
abcur ab - amitriptylinhydroklorid - tablett, filmdrasjert - 10 mg
amitriptylin abcur 25 mg
abcur ab - amitriptylinhydroklorid - tablett, filmdrasjert - 25 mg
inotyol
viatris as - iktammol / sinkoksid / titandioksid - salve - 15 mg/ g / 150 mg/ g / 50 mg/ g
plenadren
takeda pharmaceuticals international ag ireland branch - hydrokortison - binyreinsuffisiens - kortikosteroider for systemisk bruk - behandling av adrenal insuffisiens hos voksne.
mezavant 1200 mg
takeda pharmaceuticals international ag ireland branch - mesalazin - enterodepottablett - 1200 mg
adempas
bayer ag - riociguat - hypertensjon, pulmonal - antihypertensive midler for pulmonal arteriell hypertensjon - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. effekten har vært vist i en pah befolkningen, herunder aetiologies av idiopatisk eller heritable pah eller pah assosiert med bindevev sykdom. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.
bondenza (previously ibandronic acid roche)
roche registration ltd. - ibandronsyre - osteoporose, postmenopausale - legemidler til behandling av bein sykdommer - behandling av osteoporose hos postmenopausale kvinner med økt risiko for brudd. en reduksjon i risiko for vertebrale frakturer har blitt vist. effekten på femoral-hals brudd har ikke blitt etablert.